2. OVERVIEW
What are xenobiotics
What is biotransformation
Sites of biotransformation
Drug metabolising enzymes
Phase I reactions
Phase II reactions
Factors affecting biotransformation reaction
Role of biotransformation in new drug development
Conclusion
Dr. Jerin James 2
3. XENOBIOTICS
Xenobiotics are substances foreign to the body
Xenos – foreign , bios – life
Can be from:
Natural sources –e.g. plant products, alkaloids, poisons
Artificially manufactured – e.g.drugs, chemicals , pesticides
Dr. Jerin James 3
4. DEFINITION :BIOTRANSFORMATION
•Enzyme catalysed
•Biochemical transformation of drug
•Within living organism
•Lipid soluble drug/metabolite → water soluble form
•Excreted through the kidney
•Mainly Liver
•Also kidney,intestine,adrenal cortex,lungs,placenta,skin
Dr. Jerin James 4
7. OUTCOMES OF
BIOTRANSFORMATION
1. Formation of active metabolite from inactive/prodrug.,
Telampicillin → Ampicillin
2. Formation of inactive drug from pharmacologically active
drug.,
2. Phenobarbitone → hydroxyphenobarbitone
3. Formation of an active drug from an equally active drug.,
Diazepam → Oxazepam
4. Formation of toxic metabolites
5. Change in pharmacological action/new action .,
Iproniazid → Isoniazid
(antidepressant) (antitubercular)
Dr. Jerin James 7
8. PHASES OF BIOTRANSFORMATION
REACTIONS
Drug oxdn/redn/ congugtn prdt
hydrolysis
Dr. Jerin James 8
PHASE I PHASE II
Some drugs directly enter Phase II
metabolism
Following Phase I the
drug may be activated,
unchanged or
inactivated
Conjugated
drug is usually
inactive
DRUG
9. PHASE I REACTIONS
Degradative reactions
Drug is converted to a smaller polar/non polar metabolite
By introduction of a new functional group
Mainly microsomal reactions
Few are non-microsomal
Oxidation, Reduction , Hydrolysis
Metabolites formed may be active/inactive
Dr. Jerin James 9
10. PHASE II REACTIONS
=Synthetic reactions
= conjugation reactions
Makes molecule more polar
Reactions are catalysed by microsomal/
mitochondrial/cytoplasmic enzymes
Metabolite formed is polar, water soluble , inactive
Dr. Jerin James 10
11. FIRST PASS METABOLISM/
PRE-SYSTEMIC ELIMINATION/
FIRST PASS EFFECT
Metabolism of a drug
That occur before drug entering systemic circulation
Occur for drugs that are taken orally
Significant amount of drug is inactivated before reaching systemic
circulation
Certain amount of drug is absorbed as it passes through GIT wall and
portal circulation
↓d bioavailability of the drug
Diminished therapeutic effect
Imipramine,morphine,propranolol,buprenorphine,lignocaine,testostero
ne
Bypassed by parenteral administration of drug Dr. Jerin James 11
13. MICROSOMAL
ENZYMES
Smooth endoplasmic reticulum of liver mainly &
intestinal mucosa, lung and kidney , between the
phospholipid bilayer
Principal enzymes- Mixed function Oxidases(
MFO) or Cytochrome P-450
Most important pathway of drug metabolism
They are a superfamily of enzymes,all of which
contain an iron containing protein –Heme
Hemoproteins
Heme contains one atom of iron in hydrocarbon
cage, that functions to bind O2 in the CYP active site
Enzyme in reduced f give a product whose
absorption peak is at 450 cm-1
e.g. glucoronyl trsnsferase
Non specific action
Can be induced/activated
Can metabolise only lipid soluble drugs
Cytochrome P450 = CYPDr. Jerin James 13
14. LOCATION
OF CYP
Goodman & Gilman, The pharmacological basis of therapeutics, 13th ed ,page 88 Dr. Jerin
James 14
15. CYTOCHROME P
450
Classified into families designated by no.’s 1,2,3
Subfamilies designated by letters A,B,C,D
Amino acid sequence
cDNA cloning studies
• Another number is added to indicate specific
isoenzyme
eg CYP 2D6
Dr. Jerin James 15
16. CYTOCHROME P
450
Important CYPs for drug metabolism :
CYP 3A
CYP 2D
CYP 2C
• Exhibit genetic polymorphism
• Result in interindividual variation in drug response
Dr. Jerin James 16
17. CYP 3A 4 & CYP 3A5
• Substrates
oSteroids
oMacrolides
oCCB
oHormones
oAntihistamines
Induced by
oBarbiturates
oCarbamazepine
oPhenytoin
oRifampicin
Inhibitted by(‘zole’ drugs,mycin drugs,CCBs,antihistaminics)
oErythromycin ,Claruthromycin
oKetoconazole, Fluconazole
oVerapamil,Diltiazem
oRitonavir
oGrapefruit juice Dr. Jerin James 17
19. CYP 2C8 ,CYP 2C9
Substrates
oPhenytoin
owarfarin
Inducers
oBarbiturates
oRifampicin
Inhibitors
ofluconazole
Dr. Jerin James 19
20. CYP 2C 19
Substrate
oDiazepam
oProton pump inhibitors
oTCA
ophenytoin
Inducers
oBarbiturates
oPhenytoin
Inhibitors
oFluoxamine
oTiclopidine
ofluoxetine
Dr. Jerin James 20
21. NON-
MICROSOMAL
ENZYMES
Present in cytoplasm,
Mitochondria of hepatocytes & other tissues,
Plasma
eg. MAO, Esterases, Amidases, Transferases &
Conjugages
Catalyse Phase II reactions (except glucuronide
conjugation), certain oxidations, reductions &
hydrolytic reactions
Non- inducible
Can be inhibited
Shows genetic variations
eg pseudocholine esterase ,Acetyl transferase
Dr. Jerin James 21
22. PHASE I REACTIONS/
NON-SYNTHETIC REACTIONS
Oxidation, Reduction, Hydrolysis
Makes molecule more susceptible to Phase II reactions
Involve addition/uncovering of a reactive group
This functional group can be acted upon by phase II/ conjugating
enzymes
Dr. Jerin James 22
24. PHASE I REACTIONS/
NON-SYNTHETIC REACTIONS
N-O-S- dealkylation
N-dealkylation: removal of one alkyl group from amino nitrogen
eg. Morphine → normomorphine
Mephobarbitone → phenobarbitone
O-dealkylation : removal of one alkyl group from
eg. phenacetin → paracetamol
S-dealkylation: removal of one alkyl group from
eg. 6 methyl thiopurine → mercaptopurine
N- & S- oxidation:
Eg. Chlorpromazine → chlorpromazine sulfoxide
Dr. Jerin James 24
25. PHASE I REACTIONS/
NON-SYNTHETIC REACTIONS
Deamination
eg.amphetamine → phenyl acetone derivative
Desulfurisation
eg.parathion → paraoxon
Dr. Jerin James 25
26. PHASE I REACTIONS/
NON-SYNTHETIC REACTIONS
2. NON-MICROSOMAL OXIDATION (CYP Independent)
Mitochondrial oxidation
eg. epinephrine → VMA
Cytoplasmic oxidation
eg. alcohol → acetaldehyde → acetic acid
Plasma oxidative process
eg.histamine → imidazole acetic acid
Dr. Jerin James 26
27. PHASE I REACTIONS/
NON-SYNTHETIC REACTIONS
CYP P 450 independent oxidation enzymes:
Flavin Mono Oxygenases(FMO)
Alcohol Dehydrogenase(ADH)
Aldehyde oxidase
Xanthine oxidase
Peroxidase
Prostaglandin synthase
myeloperoxidase
Dr. Jerin James 27
30. PHASE I REACTIONS/
NON-SYNTHETIC REACTIONS
HYDROLYSIS
Microsomal hydrolysis
Pethidine → pethidinic acid
Hepatic membrane bound esterase
Non microsomal hydrolysis
by estrases and amides
Procaine → PABA
Atropine → Tropic acid
Dr. Jerin James 30
31. PHASE II REACTIONS/
SYNTHETIC REACTIONS
MICROSOMAL CONJUGATION
GLUCORONIDE CONJUGATION
Parent drug/Phase I metabolite that contain phenolic, alcoholic, carboxylic, amino/mercapto
groups
Undergo conjugation reaction with UDP glucuronic acid
Catalysed by UDP glucoronyl transferase enzyme
→ drug-glucuronide conjugate, polar, readily excreted
→inactive products ,( except morphine glucuronide which is active)
Drug + UDPGA → Drug-glucuronide + UDP
Glucoronyl transferase
Eg. Morphine, paracetamol, aspirin
Dr. Jerin James 31
32. PHASE II REACTIONS/
SYNTHETIC REACTIONS
NON MICROSOMAL CONJUGATION
1. N-Acetylconjugation (cytosol)
N-acetyl transferase
Acetyl CoA – co factor
R-NH2 → R-NH.CO.CH3
N-acetyl transferase
Acetyl CoA
Isoniazid, PAS , Dapsone, Sulfonamides
Dr. Jerin James 32
33. PHASE II REACTIONS/
SYNTHETIC REACTIONS
2. Sulfate conjugation ( cytosol)
Sulfotransferases
3’phospho adenosine 5-Phospho sulfate(PAPS) – cofactor
Sulfate conjugates are highly polar →excreted in urine
eg. Aspirin, methyl dopa, paracetamol, corticosteroids
Dr. Jerin James 33
34. PHASE II REACTIONS/
SYNTHETIC REACTIONS
3. Amino acid conjugation (Mitochondria)
Coupling with glycine/glutamine
Glycine transferase
Acetyl CoA – cofactor
Eg. Aspirin , Benzoic acid, Nicotinic acid
Dr. Jerin James 34
36. PHASE II REACTIONS/
SYNTHETIC REACTIONS
5. Glutathione conjugation (cytoplasm/microsomes)
Glutathione –S-transferase enzyme
Eg. Epoxides, No2 group containing drugs
Dr. Jerin James 36
37. PHASE II REACTIONS/
SYNTHETIC REACTIONS
6. Ribosides & Riboside phosphates
Formation of ribonucleosides & ribonucleotides
by purines and antimetabolites used in cancer chemotherapy
Dr. Jerin James 37
38. NON ENZYMATIC BIOTRANSFORMATION
(HOFFMANN E4LIMINATION)
Metabolism in the plasma spontaneously
Molecular rearrangement
Without enzyme action
Eg. Atracurium
Dr. Jerin James 38
39. SOME PECULIARITIES IN
BIOTRANSFORMATION
Phase II reaction before phase I
Same drug can be metabolised by different drugs simultaneously
e.g. Amitryptiline metabolised by CYP 2D6, 2C9 AND 2C19
Same CYP can metabolise different drugs simultaneously
e.g. CYP3A4 can bind and metabolize diazepam and testosterone simultaneously
Dr. Jerin James 39
ISONIAZID
N-ACETYL
CONJUGATE
(phase II )
HYDROLYSIS
(Phase I )
40. FACTORS AFFECTING
BIOTRANSFORMATION
1. Physico chemical properties of the drug
Molecular size
Acidity/basicity
Pka
Lipophilicity
Interaction with drug metabolising enzymes
2. Chemical properties of the drug
Enzyme induction
Enzyme inhibition
Environmental chemicals
3. Biological factors – age ,sex, diet..
Dr. Jerin James 40
41. FACTORS AFFECTING
BIOTRANSFORMATION
Dr. Jerin James 41
Enzyme induction
Xenobiotics induce metabolism of its own (auto metabolism) or other drugs by
binding to nuclear receptor and activating expression of target genes by
transcription
Goodman & Gilman, The pharmacological basis of therapeutics, 13th ed ,page 88
Goodman & Gilmans , The pharmacological basis of therapeutics, 13th Ed p-
42. FACTORS AFFECTING
BIOTRANSFORMATION
Enzyme inducers induce CYPs ,increase metabolism of many other drugs , resulting
in therapeutic failure
Eg. Barbiturates, Carbamazepine, Glutethimide, Griseofulvin, Phenytoin
,Primidone, Rifabutin, Rifampicin etc
th
Dr. Jerin James 42
43. FACTORS AFFECTING
BIOTRANSFORMATION
Enzyme inhibition
Enzyme inhibitors decrease drug metabolising capacity of CYPs
Inhibitors compete for active site of CYPs – drug cannot bind
Result in increase in drug level – that lead to drug toxicity
The potency of the inhibitor is determined by lipophilicity and strength of bond
between inhibitor and active site of CYP
Eg. Amiodarone, Clarithromycin, Clotrimazole, Erythromycin, Ketoconazole,
Metronidazole, Chloroquine, Ritonavir, Grape fruit juice etc
Dr. Jerin James 43
44. FACTORS AFFECTING
BIOTRANSFORMATION
Genetic variation
Drugs can behave diffferntly in different individuals due to genetic variations
Eg. People lacking Pseudo-choline esterase due to genetic variation , prolonged
apnoea can occur when Succinyl choline is administered
Goodman & gilmans. The pharmacoliogicla basis of therapeutics, 13th Ed
Dr. Jerin James 44
45. ROLE OF BIOTRANSFORMATION IN DRUG
DEVELOPMENT PROCESS
Two key elements of new drug development, Efficacy and Safety are directly
related to drug biotransformation.
The capacity to metabolise xenobiotics has made development of drugs more
time consuming and costly ,partly due to
Species difference in expression of enzymes that metabolise drugs &
thereby limit the utility of animal models to predict drug effects in humans
Interindividual variations in the capacity of humans to metabolise drugs
Drug-drug interactions involving xenobiotic metabolising enzymes
Metabolic activation of chemicals to toxic and carcinogenic derivatives
Dr. Jerin James 45
46. ROLE OF BIOTRANSFORMATION IN DRUG
DEVELOPMENT PROCESS
COMPUTER BASED (IN SILICO)
SYSTEMS
1. COMPACT
2. Camitro
3. META
4. MetabolExpert
5. METEOR
IN-VITRO SYSTEMS
1. Human liver S9 fractions
2. Human liver microsomes
3. Huan liver cytosol fractions
4. Hep G2 cell line
5. BC2 cell line
Dr. Jerin James 46
47. ROLE OF BIOTRANSFORMATION IN DRUG
DEVELOPMENT PROCESS
Human liver S9 fractions
Most widely used In-Vitro system for metabolic screening in new drug
development
Contain both Phase I and Phase II metabolic enzymes
The microsomes component of the S9 fraction contain cytochrome P450 isoforms
(phase I metabolism) and other enzyme activities. The cytosolic portion contains
the major part of the activities of transferases(phase II metabolism).
Relatively inexpensive
Easy to use
Can be automated comprehensive and high quality data at reasonable expense for
drug discovery programs
Dr. Jerin James 47
48. CONCLUSION
Xenobiotics are any substances foreign to the body
Biotransformation aims to convert water insoluble drugs/substances to water
soluble form and is excreted via kidney/bile.
In phase I reaction, addition of functional group dramatically changes the biological
property of the xenobiotic
CYP 450 is the principal enzyme of phase I reactions
In phase II reaction, the phase I metabolite is conjugated to increase the water
solubility
Biotransformation can determine the efficacy and toxicity of a drug by controlling
its biological t ½
Dr. Jerin James 48
49. CONCLUSION
Different factors that influence xenobiotic metabolism
CYP inducers and inhibitors are the most important cause for drug-drug interactions
Prediction of metabolism and ADRs by knowledge of biotransformation with
modern in vitro and in silico methods are emerging as the most important part in
new drug development process
Dr. Jerin James 49
50. References
1. K.D. Tripathi, Essentials of medical pharmacology, 7th Ed
2. Goodmann &Gilmann, Pharmacological Basis of Therapeutics,13th Ed
3. H.P. Rang, M.M.Dale,J.M. Ritter,P.KMoore Pharmacology, 5th Ed
4. Sharma & Sharma
Dr. Jerin James 50